Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease.
Andringa
G
G
Department of Neurology, Vrije Universiteit, Amsterdam, The Netherlands.
Vermeulen
R J
RJ
Drukarch
B
B
Stoof
J C
JC
Cools
A R
AR
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000978:Antiparkinson Agents; D001552:Benzazepines / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology*; D000882:Haplorhini; D007980:Levodopa / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism*; D019257:Quinpirole / Q000494:pharmacology*; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D017447:Receptors, Dopamine D1 / Q000187:drug effects / Q000502:physiology
D000978:Antiparkinson Agents; D001552:Benzazepines; D018491:Dopamine Agonists; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D019257:Quinpirole; D007980:Levodopa; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; C067113:SK&F 81297; C080703:SK&F 83959; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine